Prognosis
U.S. Trial of Lilly Antibody Therapy to End; No Safety Issue
- Federal researchers didn’t see safety risk after pausing trial
- NIH sees no benefit from therapy in hospitalized patients
This article is for subscribers only.
A paused clinical trial of an Eli Lilly & Co. experimental antibody therapy won’t resume after federal researchers concluded the drug likely wouldn’t help hospitalized Covid-19 patients with advanced cases.
The National Institutes of Health researchers who initially halted the trial due to a safety concern, however, didn’t find that the treatment caused any harm, which may bode well for a regulatory review of the antibody’s use in a different setting.